- Home
- AMSC vs VRDN Comparison
AMSC vs VRDN Comparison
Compare AMSC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMSC | VRDN |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMSC | VRDN |
|---|---|---|
| Price | $32.09 | $23.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $52.00 | $35.46 |
| AVG Volume (30 Days) | 765.5K | ★ 1.9M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1806.25 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $900,000.00 | ★ $5,706,000.00 |
| Revenue This Year | $34.98 | $13.73 |
| Revenue Next Year | $21.38 | $279.00 |
| P/E Ratio | $160.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.87 | $13.18 |
| 52 Week High | $70.49 | $34.29 |
Technical Indicators
Market Signals| Indicator | AMSC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 68.75 |
| Support Level | $29.35 | $17.97 |
| Resistance Level | $33.70 | $33.71 |
| Average True Range (ATR) | 1.98 | 1.03 |
| MACD | 0.46 | 0.13 |
| Stochastic Oscillator | 69.94 | 88.31 |
Price Performance
Historical ComparisonAbout AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.